Donna Felsenstein

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
Jump to: navigation, search


Donna Felsenstein, M.D., is an Internal Medicine and Infectious Disease physician who practices at the Massachusetts General Hospital, Boston, MA, US[1] and is a Assistant Professor of Medicine at Harvard Medical School and Massachusetts General Hospital (MGH).[2] She serves as a member of the scientific team with the Open Medicine Foundation.[2] Since 1979, she has been diagnosing and caring for patients with ME/CFS.[2] Her listed specialities include Lyme disease, Infectious diseases, and Herpes simplex virus.[1]

Notable studies[edit | edit source]

  • 2010, Xenotropic murine leukemia virus-related virus prevalence in patients with chronic fatigue syndrome or chronic immunomodulatory conditions[3] - (Full text)
  • 2015, Distinct plasma immune signatures in ME/CFS are present early in the course of illness[4] - (Full text)
  • 2015, Findings from a clinical and laboratory database developed for discovery of pathogenic mechanisms in myalgic encephalomyelitis/chronic fatigue syndrome[5] - (Abstract)

Clinic location[edit | edit source]

55 Fruit St, Boston, MA 02114

Phone: (617) 726-3812

Talks and interviews[edit | edit source]

Online presence[edit | edit source]

See also[edit | edit source]

Learn more[edit | edit source]

References[edit | edit source]

  1. 1.01.1 "Donna Felsenstein, MD - Infectious Diseases - Massachusetts General Hospital, Boston, MA". www.massgeneral.org. Retrieved September 3, 2019.
  2. 2.02.12.2 "ME/CFS Collaborative Research Center at Harvard, funded by OMF". Open Medicine Foundation. Retrieved September 3, 2019.
  3. Henrich, Timothy J.; Li, Jonathan Z.; Felsenstein, Donna; Kotton, Camille N.; Plenge, Robert M.; Pereyra, Florencia; Marty, Francisco M.; Lin, Nina H.; Grazioso, Paul (November 15, 2010). "Xenotropic Murine Leukemia Virus–Related Virus Prevalence in Patients with Chronic Fatigue Syndrome or Chronic Immunomodulatory Conditions". The Journal of Infectious Diseases. 202 (10): 1478–1481. doi:10.1086/657168. ISSN 0022-1899. PMC 2957553. PMID 20936980.
  4. Hornig, M; Montoya, JG; Klimas, NG; Levine, SM; Felsenstein, D; Bateman, L; Peterson, DL; Gottschalk, CG; Schultz, AF; Che, X; Eddy, ML; Komaroff, AL; Lipkin, WI (2015). "Distinct plasma immune signatures in ME/CFS are present early in the course of illness". Science Advances. 1 (1). doi:10.1126/sciadv.1400121.
  5. Klimas, N.G.; Ironson, G.; Carter, A.; Balbin, E.; Bateman, L.; Felsenstein, D.; Levine, S.; Peterson, D.; Chiu, K.; Allen, A.; Cunningham, K.; Gottschalk, C.G.; Fletcher, M; Hornig, M.; Canning, C.; Komaroff, A.L. (2015), "Findings from a clinical and laboratory database developed for discovery of pathogenic mechanisms in myalgic encephalomyelitis/chronic fatigue syndrome", Fatigue: Biomedicine, Health & Behavior, 3 (2): 75-96, doi:10.1080/21641846.2015.1023652

Category:immunomodulators|immunomodulator]]

immunomodulator a substance that affects the functioning of the immune system

The information provided at this site is not intended to diagnose or treat any illness.
From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history.